Is Sionna Therapeutics, Inc. (SION) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.6% / 30% | 9.2% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.6% / 33% | 9.2% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 5.2% / 33% | 79.4% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.6% / 33% | 9.2% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 5.2% / 33% | 79.4% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -31.8% | |
| Return on Assets (ROA) | -21.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$66M |
| Free Cash Flow | -$67M |
| Total Debt | $9M |
| Debt-to-Equity | 2.8 |
| Current Ratio | 20.6 |
| Total Assets | $326M |
Price & Trading
| Last Close | $37.96 |
| 50-Day MA | $38.01 |
| 200-Day MA | $31.36 |
| Avg Volume | 280K |
|
52-Week Range
$7.25
| |
About Sionna Therapeutics, Inc. (SION)
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Sionna Therapeutics, Inc. (SION) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Sionna Therapeutics, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Sionna Therapeutics, Inc.'s debt ratio?
Sionna Therapeutics, Inc.'s debt ratio is 0.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 5.2%.
What are Sionna Therapeutics, Inc.'s key financial metrics?
Sionna Therapeutics, Inc. has a market capitalization of $1.6B. Return on equity stands at -31.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.